Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…Abstract Number: 1735 • ACR Convergence 2021
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…Abstract Number: 1734 • ACR Convergence 2021
Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…Abstract Number: 1730 • ACR Convergence 2021
Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS
Background/Purpose: SpA is a severe chronic inflammatory disease, which affects quality of life and functional status. It frequently occurs in women of childbearing age. Active…Abstract Number: 1714 • ACR Convergence 2021
Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases
Background/Purpose: Few studies have comprehensively evaluated the information needs and priorities that men with rheumatic diseases have about their sexual and reproductive health (SRH). This…Abstract Number: 1741 • ACR Convergence 2021
Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
Background/Purpose: In 2 phase 3 trials, TULIP-1 and TULIP-2, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 Here, we…Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…Abstract Number: 1733 • ACR Convergence 2021
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…Abstract Number: 1739 • ACR Convergence 2021
SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity versus placebo in patients with moderate…Abstract Number: 1705 • ACR Convergence 2021
The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users
Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…Abstract Number: 1727 • ACR Convergence 2021
Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes
Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It…Abstract Number: 1718 • ACR Convergence 2021
Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide
Background/Purpose: SLE is an autoimmune disease which predominantly affects women of childbearing age (age 20-40). Most of the medications used for treating SLE can adversely…Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…Abstract Number: 1597 • ACR Convergence 2021
Arthritis Patient Perspectives on Virtual Care for People Living with Arthritis During the COVID-19 Pandemic and for the Future
Background/Purpose: Virtual Care (VC) is the delivery of health care services and information by electronic methods (video, smartphones, email, text) and may support arthritis patients…Abstract Number: 1610 • ACR Convergence 2021
“You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians
Background/Purpose: A rapid shift to telehealth visits has been a key part of health system response to the ongoing COVID-19 pandemic. This study explores the…
- « Previous Page
- 1
- …
- 546
- 547
- 548
- 549
- 550
- …
- 2425
- Next Page »